Weifa ASA: Launches Bronkyl forte 600 mg to drive growth in the Cough & Cold category

9/16/2015, 8:31 AM (Source: GlobeNewswire)
Launches Bronkyl forte 600 mg to drive growth in the Cough & Cold category

Weifa ASA is proud to announce the launch of Bronkyl forte 600 mg effervescent tablets, a new line extension to the already well established Bronkyl 200 mg. Bronkyl 200 mg is as per today the 6th most sold OTC product in Norway. The addition of a new 600 mg line extension is expected to strengthen further the brand.

"Our ambition for the Bronkyl brand is to become market leader within the OTC cough segment (measured by value) in Norway. The launch of Bronkyl forte, combined with a strong pipeline, is another step towards achieving our goal to be the fastest growing company in the Cough & Cold category in Norway" says CEO Kathrine Gamborg Andreassen in Weifa ASA.

Bronkyl forte contains acetylcysteine which is a mucolytic agent helping clear your chest from unwanted mucus. This new 600 mg strength makes it possible to have a dosage of only one effervescent tablet per day.

From 15 September 2015, Bronkyl forte in 10 tablets package will be available without prescription in all pharmacies in Norway. The launch will be supported by a solid communication campaign both towards the end user and the medical staff.

 
 

Further information from:

Kathrine Gamborg Andreassen
CEO
+47 95 17 86 80
kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen
CFO
+47 98 20 63 55
simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no

 
 
 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire

HUG#1952361
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.